Aktis Oncology rallies $72m Series A

Aktis Oncology, a biotechnology company focused on treating solid tumor cancers, has secured $72 million in Series A financing.

Aktis Oncology, a biotechnology company focused on treating solid tumor cancers, has secured $72 million in Series A financing. The investors were MPM Capital, EcoR1 Capital, Vida Ventures, Octagon Capital, TCG Crossover, Novartis and Bristol Myers Squibb.

Source: Press Release